Conference Proceedings
RESULTS OF THE ZERO CHILDHOOD CANCER INTEGRA-TM PRECISION MEDICINE PLATFORM FOR PAEDIATRIC HIGH-RISK BRAIN TUMOURS
Maria Tsoli, Loretta Lau, Paulette Barahona, Chelsea Mayoh, Tim Failes, Marie Wong, Alexandra Sherstyuk, Andrew J Gifford, Amit Kumar, Emily Mould, Caitlin Ung, Ornella Tolhurst, Anjana Gopalakrishnan, Dylan Grebert-Wade, Patrick Strong, Peter Trebilcock, Richard Lock, Vanessa Tyrrell, Toby Trahair, Katherine Tucker Show all
NEURO-ONCOLOGY | OXFORD UNIV PRESS INC | Published : 2019
Abstract
Brain tumours represent the most common solid tumour of childhood and result in significant morbidity and mortality. The Zero Childhood Cancer national child precision medicine program aims to identify targeted therapeutic agents for high-risk paediatric malignancies (expected survival <30%) including brain tumours. Here we will report on the Pilot Feasibility Study (TARGET) and the initial experience of the National Clinical Trial (PRISM), which opened in September of 2017. A total of 200 patients have been enrolled, 59 in the pilot phase (TARGET) and 141 in the National study (PRISM) out of which 77 patients (38.5%) had CNS malignancies, of which 64 cases have completed curation. Molecular..
View full abstract